The company reported on its development of a deep learning model to predict gene expression of tumors from whole slide images without the need to sequence RNA.
The company has developed a microscopy system that allows imaging of a full pathology slide in 21 channels with a single staining process and a rapid turnaround time.
The partners are preparing to release two updates to Navify Tumor Board that support automatic importation of structured Foundation Medicine test reports.
After slow, organic growth in imaging, the Spanish startup is courting major healthcare companies for a buyout as the genomics market presents major opportunities.
The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
